Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ozen Tunay, Z.; Ustunyurt, Z.; Idil, A. Causes of severe visual impairment in infants and methods of management. Eye 2021, 35, 1191–1197. [Google Scholar] [CrossRef] [PubMed]
- Hong, E.H.; Shin, Y.U.; Bae, G.H.; Choi, Y.J.; Ahn, S.J.; Sobrin, L.; Hong, R.; Kim, I.; Cho, H. Nationwide incidence and treatment pattern of retinopathy of prematurity in South Korea using the 2007–2018 national health insurance claims data. Sci. Rep. 2021, 11, 1451. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, C.A.; Chen, T.A.; Hernandez-Boussard, T.; Moshfeghi, A.A.; Moshfeghi, D.M. The epidemiology of retinopathy of prematurity in the United States. Ophthalmic Surg. Lasers Imaging Retin. 2017, 48, 553–562. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.J.; Port, A.D.; Swan, R.; Campbell, J.P.; Chan, R.V.P.; Chiang, M.F. Retinopathy of prematurity; a review of risk factors and their clinical significance. Surv. Ophthalmol. 2018, 63, 618–637. [Google Scholar] [CrossRef] [PubMed]
- Repka, M.X.; Palmer, E.A.; Tung, B. Involution of retinopathy of prematurity. Cryotherapy for retinopathy of prematurity cooperative group. Arch. Ophthalmol. 2000, 118, 645–649. [Google Scholar] [CrossRef] [PubMed]
- Hansen, E.D.; Hartnett, M.E. A review of treatment for retinopathy of prematurity. Expert Rev. Ophthalmol. 2019, 14, 73–87. [Google Scholar] [CrossRef] [PubMed]
- Kieselbach, G.F.; Ramharter, A.; Baldissera, I.; Kralinger, M.T. Laser photocoagulation for retinopathy of prematurity; structural and functional outcome. Acta Ophthalmol. Scand. 2006, 84, 21–26. [Google Scholar] [CrossRef] [PubMed]
- Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity; results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol. 2003, 121, 1684–1694. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Ren, X.; Shen, L.; Yanni, S.E.; Leffler, J.N.; Birch, E.E. Development of refractive error in individual children with regressed retinopathy of prematurity. Investig. Ophthalmol. Vis. Sci. 2013, 54, 6018–6024. [Google Scholar] [CrossRef] [PubMed]
- Mintz-Hittner, H.A.; Kennedy, K.A.; Chuang, A.Z.; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl. J. Med. 2011, 364, 603–615. [Google Scholar] [CrossRef] [PubMed]
- Stahl, A.; Lepore, D.; Fielder, A.; Fleck, B.; Reynolds, J.D.; Chiang, M.F.; Li, J.; Liew, M.; Maier, R.; Zhu, Q.; et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW); an open-label randomised controlled trial. Lancet 2019, 394, 1551–1559. [Google Scholar] [CrossRef] [PubMed]
- Stahl, A.; Sukgen, E.A.; Wu, W.C.; Lepore, D.; Nakanishi, H.; Mazela, J.; Moshfeghi, D.M.; Vitti, R.; Athanikar, A.; Chu, K.; et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity; the firefleye randomized clinical trial. JAMA 2022, 328, 348–359. [Google Scholar] [CrossRef] [PubMed]
- International Committee for Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch. Ophthalmol. 2005, 123, 991–999. [Google Scholar] [CrossRef] [PubMed]
- Lu, X.; Sun, X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des. Dev. Ther. 2015, 9, 2311–2320. [Google Scholar]
- Spandau, U.; Kim, S.J. Pediatric Retinal Vascular Diseases; From Angiography to Vitrectomy, 1st ed.; Springer: Berlin/Heidelberg, Germany, 2019; Chapter 17; pp. 139–143. [Google Scholar]
- Erol, M.K.; Coban, D.T.; Sari, E.S.; Bilgin, A.B.; Dogan, B.; Ozdemir, O.; Tunay, Z.O. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq. Bras. Oftalmol. 2015, 78, 340–343. [Google Scholar] [CrossRef] [PubMed]
- Alyamaç Sukgen, E.; Çömez, A.; Koçluk, Y.; Cevher, S. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity; a comparison study between ranibizumab and bevacizumab. Ophthalmologica 2016, 236, 139–147. [Google Scholar] [CrossRef] [PubMed]
- Gunay, M.; Sukgen, E.A.; Celik, G.; Kocluk, Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in turkey. Curr. Eye Res. 2017, 42, 462–469. [Google Scholar] [CrossRef] [PubMed]
- Ling, K.P.; Liao, P.J.; Wang, N.K.; Chao, A.N.; Chen, K.J.; Chen, T.L.; Hwang, Y.S.; Lai, C.C.; Wu, W.C. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina 2020, 40, 1793–1803. [Google Scholar] [CrossRef] [PubMed]
- Iwahashi, C.; Utamura, S.; Kuniyoshi, K.; Sugioka, K.; Konishi, Y.; Wada, N.; Kusaka, S. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina 2021, 41, 2261–2268. [Google Scholar] [CrossRef] [PubMed]
IVB | IVR | p Value | |
---|---|---|---|
male (%) | 4 (50) | 5 (62.5) | 0.673 a |
GA at birth (wks, mean ± SD) | 25.4 ± 1.7 | 25.1 ± 1.8 | 0.942 b |
weight at birth (g, mean ± SD) | 643.4 ± 211.0 | 622.3 ± 208.0 | 0.804 b |
GA at treatment (wks, mean ± SD) | 35.5 ± 3.4 | 34.5 ± 2.1 | 0.664 b |
weight at treatment (g, mean ± SD) | 1493.4 ± 395.9 | 1284.2 ± 368.0 | 0.238 b |
Apgar Score at 1 min (mean ± SD) | 3.3 ± 2.1 | 2.8 ± 2.2 | 0.505 b |
Apgar Score at 5 min (mean ± SD) | 6.0 ± 2.5 | 6.5 ± 1.9 | 0.581 b |
duration of respirator use (days, mean ± SD) | 117.4 ± 84.2 | 68.8 ± 26.4 | 0.277 b |
Blood transfusion (%) | 8 (100) | 11 (84.6) | 0.505 a |
RDS | 8 (100) | 15 (100) | NA |
severe PDA | 0 (0) | 1 (6.7) | 1.000 a |
sepsis (%) | 1 (12.5) | 3 (23.1) | 1.000 a |
IVB | IVR | p Value | |
---|---|---|---|
Zone1/2 | 5/10 | 8/16 | 1.000 a |
Stage2/3 | 6/9 | 16/8 | 0.184 a |
Plus sign (%) | 15 (100) | 24 (100) | NA |
A-ROP (%) | 1 (6.7) | 2 (8.3) | 1.000 b |
Success (%) | 14 (93.3) | 11 (45.8) | 0.00492 b |
Duration from treatment (days, mean ± SD) | 12 | 50.6 (±37.1) | NA |
Duration of follow-up from treatment (days, median (IQR)) | 221 (123, 1546) | 1210 (1114, 1421) | 0.185 b |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Takano, F.; Ueda, K.; Yamada-Nakanishi, Y.; Nakamura, M. Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity. Children 2024, 11, 927. https://doi.org/10.3390/children11080927
Takano F, Ueda K, Yamada-Nakanishi Y, Nakamura M. Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity. Children. 2024; 11(8):927. https://doi.org/10.3390/children11080927
Chicago/Turabian StyleTakano, Fumio, Kaori Ueda, Yuko Yamada-Nakanishi, and Makoto Nakamura. 2024. "Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity" Children 11, no. 8: 927. https://doi.org/10.3390/children11080927